All GLG News Analyses Filed Under: Business of Medicine

On nights, weekends, and holidays, senior healthcare professionals are rarely found in the hospital.  Problems arise from (1) too few qualified personnel available to address the needs of patients, (2) inability to obtain physician coverage for some specialties, and (3) inability to obtain and/or...

The National Association of Boards of Pharmacy (NABP) named 79 online pharmacies that are not safe for patients. Rather than a general “watch out” message, the NABP actually listed the web addresses for these rogue sources.  Many sites falsely claim to be “Canadian” pharmacies.  This was an...

-Glaxo's pre-pandemic flu vaccine is a double opportunity - a chance to contract now with multiple governments to supply a pre-pandemic vaccine as well as a natural segue to become their future supplier of actual pandemic flu vaccine (when developed).  -When pandemic flu hits, the race will be...

China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...

The Center for Medicare and Medicaid Services (CMS), the financier for the Medicare and Medicaid Programs, has decided in final regulations to permit access of its vast and rapidly growing Part D data stores to the Food and Drug Administration , other government agencies and academic researchers to...

With the recent scandals around quality, one needs to look at China's government stepping in and improving the quality. Expect additional testing requirements and regulatory requirements consider the added cost of companies sending QA teams into China to support their development

Cost of goods in China are increasing dramatically over the last few years The cost of compliance has and will increase dramatically as well. The internal regulatory costs for compliance has increased as well. Working with China is not cheap and we should look at China more as a part of a strategic...

A single payer, national system does work, but may not necessarily be in the best interest of all parties.   Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.

The Chinese government funded many manufacturing plants for biologics about 15 years ago, and many are bankrupt because of noninforced patent laws

Direct comparisons between potential competing agents often do not exist Initial FDA approval is usually based on comparisons to placebo A new approval does necessarily mean that the new agent is better than existing ones, although this is implied by industry Industry bears all the costs of efficacy...